2023年7月5日

圣地亚哥,加利福尼亚,美国圣地亚哥,05年7月,2023(全球通讯社)——Biora疗法,Inc .)(纳斯达克:BIOR),重新治疗交付的生物科技公司,今天宣布,它已完成与销售的大型诊断公司达成协议相关的遗留资产Biora前诊断业务。“这是持续进展在我们遗留资产货币化,”Eric d 'Esparbes说,首席财务官Biora疗法。“这个事务提供了增量non-dilutive资金来推进我们的治疗平台,同时使重要的诊断应用程序资产杠杆。“Biora疗法将获得一次性支付出售的资产包括权利某些抗体序列。协议的具体条款没有披露。关于Biora疗法Biora疗法治疗是生物技术公司,是畅想交付。通过创建创新智能药丸为靶向药物输送到胃肠道,和系统性,针头biotherapeutics,该公司正在开发治疗改善病人的生活。Biora专注于两种疗法的发展平台:在NaviCap™有针对性的口语交付平台,旨在改善结果为炎症性肠病的患者通过治疗胃肠道疾病的网站,和BioJet™系统性口服交付平台,旨在取代为更好的管理慢性疾病通过针头注射,口服的大分子。欲了解更多信息,请访问bioratherapeutics.com或遵循公司在LinkedIn和Twitter。安全港声明或前瞻性陈述本新闻稿中包含“前瞻性陈述”的意义的“安全港”规定的私人证券诉讼改革法案1995年,这一声明受到实质性的风险和不确定性,基于估计和假设。 All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor Contact